September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Multimodal analysis of macular toxicity following intra-arterial (IAC) and/or intravitreal (IVC) melphalan in retinoblastoma (Rb): evidence for infra-clinical changes by optic coherence tomography (OCT) and adaptive optics (AO)
Author Affiliations & Notes
  • yousra Falfoul
    Hopital Ophtalmique, Jules Gonin, Lausanne, Switzerland
  • Ali Dirani
    Hopital Ophtalmique, Jules Gonin, Lausanne, Switzerland
  • Marie-Claire Gaillard
    Hopital Ophtalmique, Jules Gonin, Lausanne, Switzerland
  • Francesco Puccinelli
    centre hospitalier universitaire vaudois, Lausanne, Switzerland
  • Maja Beck-Popovic
    centre hospitalier universitaire vaudois, Lausanne, Switzerland
  • Francis L Munier
    Hopital Ophtalmique, Jules Gonin, Lausanne, Switzerland
  • Footnotes
    Commercial Relationships   yousra Falfoul, None; Ali Dirani, None; Marie-Claire Gaillard, None; Francesco Puccinelli, None; Maja Beck-Popovic, None; Francis Munier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3683. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      yousra Falfoul, Ali Dirani, Marie-Claire Gaillard, Francesco Puccinelli, Maja Beck-Popovic, Francis L Munier; Multimodal analysis of macular toxicity following intra-arterial (IAC) and/or intravitreal (IVC) melphalan in retinoblastoma (Rb): evidence for infra-clinical changes by optic coherence tomography (OCT) and adaptive optics (AO). Invest. Ophthalmol. Vis. Sci. 2016;57(12):3683.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Melphalan chemotherapy is widely used as first line or salvage therapy for Rb with greatly improved ocular survival. To date retinal toxicity of Melphalan has been only evaluated by full field electroretinogram (ERG). Macular integrity is however the most sensitive predictor of visual prognosis. This prompted us to investigate macular structure and function by multimodal analysis following IAC and/or IVC Melphalan injections in unilateral Rb

Methods : We retrospectively reviewed all consecutive patients with unilateral group D Rb treated by IAC and/or IVC with no primary macular involvement (tumor or exudative detachment) and having reached at least 5 years of age. Patients with secondary macular detachment or vitreo-macular traction were excluded. Treated eyes were compared with fellow healthy eyes in terms of best-corrected visual acuity (VA) after amblyopia treatment, macular automated perimetry, multifocal ERG, HRA-OCT and AO. Stereopsis was evaluated on the Lang test

Results : Five patients were included with a mean cumulative melphalan dose of 12.75mg and 215µg per eye injected by IAC and IVC respectively. Mean age at last test was 7.6 years (range 5.3-13.4). Mean VA was 0.86 (range 0.7–1.0), 1.0 for all fellow eyes. 80% had stereopsis. Treated eyes had higher values of mean deviation on macular visual field examination (6.5+/-3.5dB vs 1.6+/-0.6dB; p=0.04). Multifocal ERG analysis showed no difference between the two eyes in terms of kernel 1, 2 and 3 indexes. OCT showed higher central foveal thickness in treated eyes compared to fellow eyes (180.2+/-21.7µm vs 144.2+/-13.9µm; p=0.043) and no difference in the sub-foveal and peripapillarychoroidal thickness. Quantitative AO analysis revealed that treated eyes had comparable number of cones in superior, temporal and inferior macular areas, but significantly less in the nasal macular area (14417+/-7484 cones/mm2vs 23645+/-6048 cones/mm2; p=0.043)

Conclusions : IAC and/or IVC melphalan resulted in discrete macular toxic changes consisting of an increased non-edematous foveal thickness and a significant decrease in cones nasally to the fovea. These modifications remained mostly infraclinical and compatible with a near normal visual acuity despite the presence of treated amblyopia

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×